Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients

Table 1 Comparison of the baseline data between the two groups

Group	n	Age (yr)	BMI (kg/m2)	KPS score (scores)	FIGO stage (%)			Differentiation (%)
					Stage IIB	Stage III	Stage IVA	Well differentiated	Moderately differentiated	Poorly differentiated
Test group	60	57.6 ± 6.0	23.2 ± 2.4	78.4 ± 3.0	13 (21.67)	26 (43.33)	21 (35.00)	18 (30.00)	27 (45.00)	15 (25.00)
Control group	60	55.9 ± 6.8	22.8 ± 2.7	77.8 ± 2.8	17 (28.33)	21 (35.00)	22(36.67)	23 (38.33)	20 (33.33)	17 (28.33)
t/χ2		1.452	0.858	1.133	1.825			1.565
P value		0.149	0.393	0.260	0.401			0.457

BMI: Body mass index; KPS: Karnofsky performance status; FIGO: International Federation of Gynecology and Obstetrics.

Table 2 Comparison of chemotherapy effects between the two groups

Group	n	CR	PR	SD	PD	CR + PR
Test group	60	27	24	9	0	51 (85.00)
Control group	60	21	20	17	2	41 (68.33)
χ2						4.658
P value						0.031

CR: Complete remission; PR: Partial remission; PD: Progressive disease.

Table 3 Comparison of serum marker levels between the two groups before and after chemotherapy (mean ± SD)

Group	n	TK1 (pmol/L)		HE4 (pmol/L)		VEGF (pg/mL)		SCC-Ag (ng/mL)
		Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy
Test group	60	3.64 ± 0.95	1.27 ± 0.40	138.5 ± 29.5	81.4 ± 24.0	549.6 ± 98.3	235.1 ± 38.0	6.19 ± 2.04	1.76 ± 0.55
Control group	60	3.40 ± 1.03	1.58 ± 0.51	132.0 ± 32.7	98.0 ± 28.6	541.0 ± 88.6	284.2 ± 54.1	5.95 ± 2.23	2.34 ± 0.78
t		1.327	-3.705	1.143	-3.444	0.503	-5.753	0.615	-4.707
P value		0.187	0.000	0.255	0.001	0.616	0.000	0.540	0.000

TK1: thymidine kinase 1; HE4: human epididymis protein 4; VEGF: vascular endothelial growth factor; SCC-Ag: squamous cell carcinoma-associated antigen.

Table 4 Comparison of the incidence of side effects between the two groups, n (%)

Toxic side effects	Test group (n = 60)		Control group (n = 60)		χ2	P value
	Grade 1	Grade ≥ 2	Grade 1	Grade ≥ 2
Nausea	13 (21.67)	47 (78.33)	18 (30.00)	42 (70.00)	1.087	0.297
Vomiting	19 (31.67)	41 (68.33)	24 (40.00)	36 (60.00)	0.906	0.341
Loss of appetite	24 (40.00)	36 (60.00)	20 (33.33)	40 (66.67)	0.574	0.449
Diarrhea	34 (56.67)	26 (43.33)	39 (65.00)	21 (35.00)	0.874	0.35
Neutropenia	16 (26.67)	44 (73.33)	22 (36.67)	38 (63.33)	1.386	0.239
Leukopenia	11 (18.33)	49 (81.67)	17 (28.33)	43 (71.67)	1.677	0.195
Thrombocytopenia	14 (23.33)	46 (76.67)	23 (38.33)	37 (61.67)	3.165	0.075

Table 5 Comparison of quality of life scores between the two groups before and after chemotherapy (mean ± SD, scores)

Project	Before chemotherapy		t	P value	After chemotherapy		t	P value
	Test group (n = 60)	Control group (n = 60)			Test group (n = 60)	Control group (n = 60)
Physical function	55.3 ± 6.2	53.8 ± 5.8	1.369	0.174	72.0 ± 7.4	68.8 ± 8.3	2.229	0.028
Role function	51.7 ± 5.5	53.5 ± 6.0	-1.713	0.089	70.5 ± 5.5	66.7 ± 6.5	3.457	0.001
Emotional function	48.8 ± 6.6	50.2 ± 6.2	-1.198	0.233	68.8 ± 6.6	66.5 ± 6.3	1.953	0.053
Cognitive function	58.2 ± 7.1	56.4 ± 6.6	1.438	0.153	65.0 ± 7.1	63.0 ± 7.6	1.490	0.139
Social function	65.8 ± 7.5	64.3 ± 7.2	1.118	0.266	72.1 ± 7.5	69.8 ± 7.1	1.725	0.087
Symptom scale score	229.1 ± 24.0	225.9 ± 21.4	0.771	0.442	158.4 ± 15.5	173.0 ± 18.3	-4.716	0.000

Table 6 Comparison of the 3-year progression-free survival rate and overall survival rate between the two groups, n (%)

Group	n	Progression-free survival	Overall survival
Test group	60	26 (43.33)	29 (48.33)
Control group	60	16 (26.67)	20 (33.33)
χ2		3.663	2.794
P value		0.056	0.095